Summary by Moomoo AI
Addex Therapeutics announced positive results from its GABAB positive allosteric modulator (PAM) chronic cough program, to be presented at the 13th London International Cough Symposium on July 19, 2024. In guinea pig models, the GABAB PAM candidate demonstrated significant dose-dependent reduction in citric acid-induced cough frequency, with improved safety margin compared to baclofen.The study revealed that the selective GABAB PAM showed minimal efficacious dose at 1 mg/kg, increased cough latency, and exhibited no tolerance after sub-chronic treatment. Notably, this marks the first demonstration of antitussive activity by a highly selective GABAB PAM in animal cough models, potentially offering advantages over baclofen, which is limited by side effects and short half-life.The research suggests potential for developing a best-in-class treatment for chronic cough, targeting an allosteric site of the GABAB receptor. This approach is expected to provide higher selectivity, better tolerability, and lack of tolerance compared to traditional orthosteric compounds like baclofen.
